Vagus Nerve Stimulators (VNS) Device Pipeline Assessment Report 2020: Stage of Development, Territory, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trials - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

"Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Vagus Nerve Stimulators (VNS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A VNS is a device comprised of an electrical pacemaker that sends electrical stimulation through surgically-implanted electrodes to target the vagus nerve. VNSs are utilized to treat neurological disorders like epilepsy and depression.

Scope

• Extensive coverage of the Vagus Nerve Stimulators (VNS) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Vagus Nerve Stimulators (VNS) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Vagus Nerve Stimulators (VNS) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Vagus Nerve Stimulators (VNS) Overview

3 Products under Development

3.1 Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development

3.2 Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory

3.3 Vagus Nerve Stimulators (VNS) - Pipeline Products by Regulatory Path

3.4 Vagus Nerve Stimulators (VNS) - Pipeline Products by Estimated Approval Date

3.5 Vagus Nerve Stimulators (VNS) - Ongoing Clinical Trials

4 Vagus Nerve Stimulators (VNS) - Pipeline Products under Development by Companies

4.1 Vagus Nerve Stimulators (VNS) Companies - Pipeline Products by Stage of Development

4.2 Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development

5 Vagus Nerve Stimulators (VNS) Companies and Product Overview

• Aucta Technologies Inc
• Boston Scientific Corp
• Cala Health Inc
• CerboMed GmbH
• Cyberonics Inc
• DuoCure Ltd.
• ElectroCore Inc
• LivaNova PLC
• Medical University of South Carolina
• MicroTransponder Inc
• Nemechek Technologies LLC
• Nexeon MedSystems Inc
• Otto Bock HealthCare GmbH
• Parasym Ltd
• Pulsus Medical LLC (Inactive)
• Purdue University
• Setpoint Medical Corp
• Synergia Medical
• SzeleSTIM GmbH
• The Feinstein Institute for Medical Research
• Trifectas Medical Corp.
• University of Pittsburgh
• University of Wisconsin Madison

6 Vagus Nerve Stimulators (VNS)- Recent Developments

6.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific

6.2 Mar 09, 2020: LivaNova VNS Therapy System, Symmetry, granted CE Mark for difficult-to-treat depression

6.3 Feb 26, 2020: LivaNova reports fourth quarter and full-year 2019 results

6.4 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019

6.5 Jan 27, 2020: ElectroCore announces rebate agreement with Ascent Health Services for gammaCore preferred brand coverage on all express scripts standard national formularies

6.6 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019

6.7 Jan 13, 2020: electroCore provides business update and select financial guidance

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/nhhg22

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900